Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;45(2):396-405.
doi: 10.1016/j.bj.2021.04.009. Epub 2021 Apr 30.

Breast cancer larger than 2.5 cm with tumor-free radioisotope-hot sentinel nodes has higher risk of non-hot axillary lymph node metastasis

Yu-Ling Liu  1 , Wen-Ling Kuo  2 , Yong-Feng Lo  1 , Hsiu-Pei Tsai  1 , Shih-Che Shen  1 , Chi-Chang Yu  1 , Hsu-Huan Chou  1 , Chia-Huei Chu  1 , Shin-Cheh Chen  1
Affiliations

Breast cancer larger than 2.5 cm with tumor-free radioisotope-hot sentinel nodes has higher risk of non-hot axillary lymph node metastasis

Yu-Ling Liu et al. Biomed J. 2022 Apr.

Abstract

Background: Sentinel lymph node biopsy (SLNB) is the standard axillary staging approach for early breast cancer with clinically negative axillary involvement. Adequate SLNB should include the removal of not only radioactive tracer-labeled lymph nodes (hot nodes or SLNs) but also suspicious unlabeled nodes (non-hot nodes or non-SLNs). However, the biopsy of non-hot nodes is highly dependent on the surgeons' experiences. This article aims to facilitate the surgeon's decision making by elucidating parameters that correlate with non-hot node metastasis.

Methods: From 2013 to 2016, clinically node-negative (cN0) breast cancer patients receiving axillary SLNB using single Tc-99m tracer method at our institute were recruited. Patients were excluded if they had received prior neoadjuvant chemotherapy. Among them, cases that have at least one non-isotope-hot node biopsied were retrospectively reviewed with a particular focus on patients with pathologically negative isotope-hot SLNs. The correlation of clinicopathological data with metastasis to axillary lymph nodes and sentinel lymph nodes was analyzed with the Chi-squared test, Fisher's exact test, and multivariate logistic regression. Receiver operating curve (ROC) was applied for continuous variables that predicted non-hot node metastasis; relapse-free survival (RFS) and locoregional relapse-free survival (LRRFS) were compared by Kaplan-Meier analysis.

Results: In 632 isotope-hot SLN negative patients, T stage showed a correlation with non-isotope-hot SLN metastasis (p = 0.035, odds ratio (OR) 9.65). Tumors larger than 2.5 cm best predict non-isotope-hot SLN metastasis (area under curve (AUC) = 0.71). With a median follow up of 41.80 months, locoregional relapse-free survival was significantly worse in cases with non-hot node metastasis (66.2% vs. 69.0%, p = 0.001).

Conclusion: In the setting of SLNB using single radioisotope tracer, non-hot node metastasis in cases with negative hot SLN still carries a higher locoregional recurrence rate (13.3%). For early breast cancer larger than 2.5 cm, removal of suspicious non-hot nodes should be included for a precision therapy.

Keywords: Breast cancer; Lymphovascular invasion; Sentinel lymph node; Sentinel lymph node biopsy; Tumor size.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Receiver operating curve showing cut-off of tumor size that warrants careful exploration of non-Isotope-hot nodes.
Fig. 2
Fig. 2
The rate of overall recurrence (A) and locoregional recurrence (B) of pathological node-negative, pathological node-positive, non-hot node-negative and non-hot node-positive groups after a median follow up of 41.80 months. Abbreviations used: pN-: pathological node-negative; pN+: pathological node-positive; non-hot node-: non-hot node-negative; non-hot node+: non-hot node-positive; N/S: non-significant.
Fig. 3
Fig. 3
Kaplan–Meier survival curve displaying relapse-free survival (RFS) (A) and locoregional relapse-free survival (LRRFS) (B) in pN- and pN + groups.
Fig. 4
Fig. 4
Kaplan–Meier survival curve displaying relapse-free survival (RFS) (A) and locoregional relapse-free survival (LRRFS) (B) in non-hot node-negative and non-hot node-positive groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Pan H., Gray R., Braybrooke J., Davies C., Taylor C., McGale P., et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836–1846. - PMC - PubMed
    1. Liao G.-S., Hsu H.-M., Chu C.-H., Hong Z.-J., Fu C.-Y., Chou Y.-C., et al. Prognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes. J Med Sci. 2018;38:54–61.
    1. von Minckwitz G., Procter M., de Azambuja E., Zardavas D., Benyunes M., Viale G., et al. Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122–131. - PMC - PubMed
    1. Raut C.P., Hunt K.K., Akins J.S., Daley M.D., Ross M.I., Singletary S.E., et al. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer. 2005;104:692–699. - PubMed
    1. Cimmino V.M., Brown A.C., Szocik J.F., Pass H.A., Moline S., De S.K., et al. Allergic reactions to isosulfan blue during sentinel node biopsy--a common event. Surgery. 2001;130:439–442. - PubMed

MeSH terms